Safety of ustekinumab in adolescent patients with moderate‐to‐severe plaque psoriasis: real‐world evidence from an ongoing European study (NCT03218488)

Detalles Bibliográficos
Autores principales: Mahé, E., Geldhof, A., Jazra, M., Bergmans, P., Azzabi, A., Seyger, M.M.B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Letters to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10286644/
https://www.ncbi.nlm.nih.gov/pubmed/35349743
http://dx.doi.org/10.1111/jdv.18110
_version_ 1785061794481438720
author Mahé, E.
Geldhof, A.
Jazra, M.
Bergmans, P.
Azzabi, A.
Seyger, M.M.B.
author_facet Mahé, E.
Geldhof, A.
Jazra, M.
Bergmans, P.
Azzabi, A.
Seyger, M.M.B.
author_sort Mahé, E.
collection PubMed
description
format Online
Article
Text
id pubmed-10286644
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-102866442023-06-23 Safety of ustekinumab in adolescent patients with moderate‐to‐severe plaque psoriasis: real‐world evidence from an ongoing European study (NCT03218488) Mahé, E. Geldhof, A. Jazra, M. Bergmans, P. Azzabi, A. Seyger, M.M.B. J Eur Acad Dermatol Venereol Letters to the Editor John Wiley and Sons Inc. 2022-04-06 2022-08 /pmc/articles/PMC10286644/ /pubmed/35349743 http://dx.doi.org/10.1111/jdv.18110 Text en © 2022 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Letters to the Editor
Mahé, E.
Geldhof, A.
Jazra, M.
Bergmans, P.
Azzabi, A.
Seyger, M.M.B.
Safety of ustekinumab in adolescent patients with moderate‐to‐severe plaque psoriasis: real‐world evidence from an ongoing European study (NCT03218488)
title Safety of ustekinumab in adolescent patients with moderate‐to‐severe plaque psoriasis: real‐world evidence from an ongoing European study (NCT03218488)
title_full Safety of ustekinumab in adolescent patients with moderate‐to‐severe plaque psoriasis: real‐world evidence from an ongoing European study (NCT03218488)
title_fullStr Safety of ustekinumab in adolescent patients with moderate‐to‐severe plaque psoriasis: real‐world evidence from an ongoing European study (NCT03218488)
title_full_unstemmed Safety of ustekinumab in adolescent patients with moderate‐to‐severe plaque psoriasis: real‐world evidence from an ongoing European study (NCT03218488)
title_short Safety of ustekinumab in adolescent patients with moderate‐to‐severe plaque psoriasis: real‐world evidence from an ongoing European study (NCT03218488)
title_sort safety of ustekinumab in adolescent patients with moderate‐to‐severe plaque psoriasis: real‐world evidence from an ongoing european study (nct03218488)
topic Letters to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10286644/
https://www.ncbi.nlm.nih.gov/pubmed/35349743
http://dx.doi.org/10.1111/jdv.18110
work_keys_str_mv AT mahee safetyofustekinumabinadolescentpatientswithmoderatetosevereplaquepsoriasisrealworldevidencefromanongoingeuropeanstudynct03218488
AT geldhofa safetyofustekinumabinadolescentpatientswithmoderatetosevereplaquepsoriasisrealworldevidencefromanongoingeuropeanstudynct03218488
AT jazram safetyofustekinumabinadolescentpatientswithmoderatetosevereplaquepsoriasisrealworldevidencefromanongoingeuropeanstudynct03218488
AT bergmansp safetyofustekinumabinadolescentpatientswithmoderatetosevereplaquepsoriasisrealworldevidencefromanongoingeuropeanstudynct03218488
AT azzabia safetyofustekinumabinadolescentpatientswithmoderatetosevereplaquepsoriasisrealworldevidencefromanongoingeuropeanstudynct03218488
AT seygermmb safetyofustekinumabinadolescentpatientswithmoderatetosevereplaquepsoriasisrealworldevidencefromanongoingeuropeanstudynct03218488

Ejemplares similares